
A major new study involving 25,480 Americans has found that daily marijuana use is associated with 39% lower odds of primary open-angle glaucoma, the most common form of a potentially blinding eye disease. Published November 3, 2026, in the Journal of Glaucoma, the research provides new evidence of a possible relationship between cannabis consumption and eye health. The findings renew scientific interest in cannabinoids as potential treatments for glaucoma, a condition that damages the optic nerve and can progressively destroy vision.
Researchers examined medical records and cannabis-use survey responses from thousands of participants in the National Institutes of Health’s All of Us Research Program. After adjusting for demographic and clinical factors, individuals reporting daily marijuana consumption had significantly lower odds of having primary open-angle glaucoma compared with those reporting no marijuana use. The researchers also identified an inverse relationship between consumption frequency and glaucoma diagnoses, suggesting that more frequent cannabis use was associated with lower disease odds. However, the findings do not establish that marijuana prevents glaucoma, reverses optic nerve damage, or provides an effective alternative to existing treatments.
Researchers Analyze Glaucoma and Marijuana Use in 25,480 Americans
The study, titled The Association Between Marijuana Use and Primary Open-Angle Glaucoma Using the All of Us Research Program: A Case-Control Study, was conducted by researchers affiliated with the University of California, San Diego, the University of California, Irvine, and Columbia University. The research team included Leo L. T. Meller, Alireza Kamalipour, Sally L. Baxter, Robert Weinreb, and Sasan Moghimi, among other investigators. Their objective was to determine whether marijuana use was associated with primary open-angle glaucoma in a large, racially and ethnically diverse American population.
The researchers analyzed data from 5,096 individuals diagnosed with primary open-angle glaucoma and 20,384 control participants without the condition. Electronic health records were combined with survey responses documenting marijuana consumption and frequency of use. Among participants diagnosed with glaucoma, 2,063 individuals, approximately 40%, reported having used marijuana at some point. Researchers then used statistical models to examine differences between cannabis users and nonusers while accounting for measured demographic and clinical characteristics. The large sample allowed investigators to evaluate patterns that smaller clinical studies might not detect, although the observational design placed important limits on the conclusions.
Daily Marijuana Use Associated With 39% Lower Glaucoma Odds
The most significant finding involved participants who reported using marijuana every day. After statistical adjustment, daily cannabis consumers had an odds ratio of 0.61 for primary open-angle glaucoma compared with individuals reporting no marijuana use. This corresponds to approximately 39% lower adjusted odds of having the condition. The association was statistically significant, with a reported probability value of 0.035 and a 95% confidence interval ranging from 0.38 to 0.95. Although the confidence interval was relatively wide, its upper boundary remained below 1.0, supporting the researchers’ conclusion that the observed relationship warranted further investigation.
An important distinction is that 39% lower odds does not mean marijuana reduces an individual’s future glaucoma risk by 39%. The study compared people who already had glaucoma with individuals who did not, rather than following initially healthy participants to determine whether cannabis prevented the disease. Researchers also reported that increasing marijuana-use frequency was associated with progressively lower glaucoma odds, a pattern described as an inverse dose-response relationship. In adjusted analyses, the clearest statistically significant result involved daily consumption. The findings therefore identify a potentially meaningful association, but they cannot determine whether cannabis itself produced the difference.
Understanding Glaucoma and Its Effects on Vision
Glaucoma refers to a group of eye diseases characterized by progressive damage to the optic nerve, which transmits visual information from the retina to the brain. Primary open-angle glaucoma develops when the eye’s drainage system becomes less effective over time, potentially contributing to increased intraocular pressure. Excessive pressure can damage sensitive nerve fibers, gradually reducing the visual field. However, glaucoma can also develop when eye pressure falls within a statistically normal range, indicating that additional factors influence disease progression. Age, genetics, family history, certain medical conditions, and other characteristics can contribute to an individual’s likelihood of developing glaucoma.
One of the greatest challenges in glaucoma care is that early disease frequently produces no noticeable symptoms. Vision loss often begins in the peripheral field, making it possible for substantial optic nerve damage to develop before a person recognizes a problem. As glaucoma progresses, blind spots can enlarge and interfere with everyday activities, eventually threatening central vision. Because existing treatments cannot restore nerve fibers already destroyed by the disease, early detection and consistent pressure management remain essential. Regular comprehensive eye examinations allow ophthalmologists to assess optic nerve health, measure intraocular pressure, evaluate visual fields, and identify changes that may require treatment.
Marijuana’s Relationship With Eye Pressure Has Been Studied for Decades
Scientific interest in marijuana and glaucoma began long before modern cannabis legalization. During the 1970s, researchers discovered that smoking marijuana could temporarily lower intraocular pressure in both healthy individuals and patients diagnosed with glaucoma. Subsequent investigations found similar effects following certain forms of THC administration. Some early experiments documented pressure reductions of approximately 25%, although responses varied among participants and depended on the preparation, dosage, and administration method. These findings suggested that cannabinoids interact with biological pathways involved in regulating fluid pressure inside the eye.
However, the pressure-lowering effect generally lasts only three to four hours, considerably shorter than the sustained control required to manage a chronic eye disease. Maintaining a continuous reduction in pressure through conventional marijuana consumption could require repeated dosing throughout the day and night, exposing patients to substantial intoxicating effects and other health risks. The short duration has historically limited marijuana’s usefulness as a clinical glaucoma treatment. The new study differs from those earlier investigations because it examined the relationship between cannabis consumption patterns and glaucoma diagnoses across a large population rather than measuring immediate changes in intraocular pressure following a controlled dose.
Why Ophthalmologists Still Do Not Recommend Marijuana for Glaucoma
Despite the encouraging association reported in the new research, the American Academy of Ophthalmology and the American Glaucoma Society continue to advise against using marijuana as a glaucoma treatment. Their position reflects the difference between temporarily lowering eye pressure and demonstrating long-term preservation of vision. Glaucoma management requires reliable control of intraocular pressure, often around the clock, while preventing additional optic nerve damage. Prescription eye drops, laser treatments, and surgical procedures can provide more predictable pressure reduction without requiring patients to remain continuously exposed to intoxicating THC.
Another concern involves marijuana’s effects on systemic blood pressure. Although THC may temporarily reduce pressure inside the eye, cannabis can also lower blood pressure elsewhere in the body. Reduced blood flow to the optic nerve could potentially offset the benefits of lower intraocular pressure, particularly in patients whose vision loss is influenced by inadequate ocular circulation. Frequent cannabis consumption can also produce dizziness, impaired coordination, changes in attention, and other adverse effects. The latest study did not measure whether participants using marijuana experienced slower glaucoma progression or better visual outcomes, meaning it does not provide evidence sufficient to replace established ophthalmic treatment recommendations.
THC and CBD May Have Different Effects on Eye Health
Cannabis contains numerous biologically active compounds, and their effects on eye pressure are not necessarily identical. THC, the primary intoxicating cannabinoid, interacts with receptors involved in several physiological processes, including pain perception, neurological signaling, and ocular pressure regulation. Laboratory investigations have identified cannabinoid-related receptors, including CB1 and GPR18, as possible contributors to THC’s effects on intraocular pressure. These findings have encouraged researchers to investigate whether specific cannabinoid compounds could eventually be developed into targeted medications that produce sustained pressure reduction without the broader effects associated with marijuana intoxication.
CBD, however, does not appear to produce the same consistently favorable effect on eye pressure. Research published in Investigative Ophthalmology & Visual Science in 2018 found that CBD increased intraocular pressure in mice under certain experimental conditions and could interfere with THC’s pressure-lowering effects. Smaller human studies have also raised concerns about pressure increases after particular CBD doses. These results do not establish that ordinary CBD products inevitably worsen glaucoma, but they demonstrate why cannabinoids must be evaluated individually. The 2026 population study did not identify specific cannabis formulations, cannabinoid concentrations, or consumption methods associated with the lower glaucoma odds, leaving important questions about which substances might contribute to the observed relationship.
Study Limitations Prevent Conclusions About Glaucoma Prevention
Although the study included more than 25,000 participants, several limitations prevent researchers from establishing a causal relationship between cannabis consumption and glaucoma. Its case-control design relied on existing medical records and survey responses rather than randomly assigning participants to different marijuana treatments. Individuals who regularly consume cannabis may differ from nonusers in ways that influence their likelihood of receiving a glaucoma diagnosis. Age, access to healthcare, tobacco use, other medications, socioeconomic circumstances, and underlying medical conditions could affect the results. Statistical adjustments can reduce the influence of measured factors but cannot eliminate every potential source of bias.
The study also lacked the detailed clinical measurements necessary to establish whether cannabis improved eye health over time. Researchers did not demonstrate sustained reductions in intraocular pressure, preservation of retinal nerve fibers, or slower visual field deterioration among cannabis users. The findings could also be influenced by differences in diagnosis rates or the possibility that people receiving glaucoma treatment change their marijuana consumption habits. Another consideration is that the All of Us Research Program does not represent a random sample of the entire American population, limiting how confidently the results can be generalized nationally. These uncertainties reinforce the importance of interpreting the findings as an association rather than evidence that marijuana prevents disease.
Racial and Ethnic Differences Deserve Further Investigation
The research team reported that the association between daily marijuana use and lower glaucoma odds was particularly apparent among White participants. Because the study included individuals from multiple racial and ethnic backgrounds, researchers could investigate whether the relationship appeared consistent across demographic groups. However, differences between subgroups require cautious interpretation, especially when smaller sample sizes reduce statistical precision. A stronger association in one group does not establish that cannabis has a unique protective effect for that population or that individuals from other backgrounds cannot experience similar biological responses.
Understanding demographic differences is especially important because glaucoma risk and access to eye care vary across American communities. Black Americans, for example, face elevated risks of developing certain forms of glaucoma and experiencing serious vision loss. Differences in diagnosis, healthcare access, treatment adherence, and other factors can complicate population-level research. Future studies should include sufficiently large and diverse groups to determine whether the observed cannabis association persists after accounting for these variables. Such research could also help identify whether genetic characteristics, medication use, or environmental factors influence the relationship between cannabinoids and ocular health.
Future Cannabis Research Could Reveal New Glaucoma Treatments
The authors concluded that the inverse relationship between marijuana use frequency and glaucoma status deserves further investigation, particularly through prospective studies designed to examine whether the association is causal. Following participants over several years would allow researchers to document cannabis exposure before glaucoma develops and evaluate whether different consumption patterns are associated with changes in disease incidence. Investigators could also incorporate repeated eye pressure measurements, optic nerve imaging, visual field examinations, and detailed information about other medications. These methods would provide a stronger foundation for understanding whether cannabinoids have meaningful effects on the development or progression of glaucoma.
Another promising direction involves studying individual cannabinoids rather than whole-plant marijuana. Pharmaceutical formulations could potentially target receptors involved in eye pressure regulation while minimizing intoxication, cardiovascular effects, and other adverse reactions. Researchers may also examine whether cannabinoid signaling influences inflammation, retinal cell function, or other biological processes involved in optic nerve damage. However, laboratory findings and observational associations must be confirmed through rigorous clinical testing before new treatments can be recommended. The ultimate objective would be to develop therapies that protect vision over extended periods rather than producing only temporary changes in intraocular pressure.
What the Findings Mean for Medical Marijuana Patients
For individuals already using medical marijuana, the study provides an additional reason to discuss cannabis consumption with healthcare professionals, particularly when receiving treatment for glaucoma or other eye conditions. Ophthalmologists benefit from understanding whether patients use THC, CBD, or other cannabinoid products because these substances can influence eye pressure measurements and potentially affect the interpretation of clinical examinations. Temporary pressure reductions following recent cannabis consumption could make an isolated reading appear more favorable than the patient’s usual pressure pattern. Accurate information about recent use may therefore help clinicians evaluate test results and develop appropriate treatment plans.
Patients should not begin consuming marijuana specifically to prevent glaucoma based on these findings, nor should individuals with existing diagnoses discontinue prescribed eye drops or delay necessary procedures. Established treatments have demonstrated benefits in slowing disease progression, while cannabis has not been shown to provide equivalent long-term protection. Anyone concerned about glaucoma risk should prioritize comprehensive eye examinations, particularly when older, living with a family history of the disease, or experiencing other recognized risk factors. The potential medical applications of cannabinoids remain worthy of investigation, but current evidence does not support substituting marijuana for proven vision-preserving therapies.
New Findings Add to Growing Evidence Connecting Cannabis and Eye Health
The November 2026 study represents an important contribution to cannabis research because it examines a longstanding medical question using information from a much larger and more diverse population than many earlier investigations. Its finding that daily marijuana users had 39% lower adjusted odds of primary open-angle glaucoma provides a compelling reason to investigate possible biological relationships between cannabinoids, intraocular pressure, and optic nerve health. The observed association also suggests that cannabis research may have applications beyond the conditions most frequently discussed in medical marijuana programs, including chronic pain, epilepsy, and multiple sclerosis.
Nevertheless, the distinction between scientific promise and established medical effectiveness remains essential. The research did not demonstrate that marijuana prevents glaucoma, reduces permanent vision loss, or produces better outcomes than conventional medications. Further studies must determine whether the association reflects a genuine biological effect, differences between cannabis users and nonusers, or other influences that the current analysis could not identify. For now, the findings offer an intriguing development in the history of marijuana and glaucoma research, strengthening the case for more detailed investigation while leaving existing medical guidance unchanged. If future studies identify safe cannabinoid-based treatments capable of preserving optic nerve function, the discovery could contribute to a new generation of glaucoma therapies.






